Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

NCT07648641 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.

NCT NCT07648641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07648641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
Lead sponsor
CanSino Biologics Inc.
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
December 1, 2027
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial infections, pneumococcal infections, streptococcal infections